Maurer, Marcus
Albuquerque, Mónica
Boursiquot, Jean-Nicolas
Dery, Elaine
Giménez-Arnau, Ana
Godse, Kiran
Guitiérrez, Guillermo
Kanani, Amin
Lacuesta, Gina
McCarthy, Jessica
Nigen, Simon
Winders, Tonya
Funding for this research was provided by:
Global Allergy & Airways Patient Platform
Article History
Received: 29 September 2023
Accepted: 30 October 2023
First Online: 22 November 2023
Declarations
:
: M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alvotech, Amgen, Aquestive, Aralez, AstraZeneca, Bayer, Celldex, Celltrion, Evommune, GSK, Ipsen, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Resoncance Medicine, Sanofi/Regeneron, Septerna, Trial Form Support International AB, Third HarmonicBio, ValenzaBio, Yuhan Corporation, Zurabio. M. Albuquerque has nothing to disclose. J-N. Boursiquot has nothing to disclose. E. Dery has nothing to disclose. A. Giménez-Arnau is or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceutials, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Novartis, Sanofi–Regeneron, Servier, Thermo Fisher Scientific, Uriach Pharma / Neucor. K. Godse has nothing to disclose. G. Guitiérrez has nothing to disclose. A. Kanani has nothing to disclose. G Lacuesta has received industry sponsored funding from Novartis, Astra Zeneca, Takeda; received speakers fees/advisory board fees from Novartis, Astra Zeneca, GSK, Sanofi, Abbvie, CSL Behring, Takeda. J. McCarthy is an employee of Novartis Pharmaceutical Corporation, East Hanover, NJ, USA. S. Nigen has nothing to disclose. T. Winders has nothing to disclose.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.